

February 17, 2017

DCAT**TOP**
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

DCAT
WEEK
2017**OPENING DAY****HAPPY
HOUR****Patheon.**
A HEALTHIER WORLD. DELIVERED.

Request an invitation

1. Takeda Completes \$5.2-Billion Acquisition of Ariad

Takeda Pharmaceutical has completed its previously announced \$5.2-billion acquisition of Ariad Pharmaceuticals, giving Takeda a rare-cancer therapy portfolio, including a late-stage lung-cancer drug candidate with a peak annual sales potential of over \$1 billion. [Read More](#)

2. Allergan to Acquire Medical Technology Company in \$2.5-Billion Deal

Allergan has agreed to acquire Zeltiq Aesthetics, a medical technology company with a proprietary controlled-cooling technology platform for body sculpting, in a \$2.475 billion deal. The move further boosts Allergan's medical aesthetics portfolio following its \$2.9-billion acquisition of LifeCell, a regenerative medicines company. [Read More](#)

3. Seattle Genetics in \$2-Billion ADC Deal

Seattle Genetics has partnered with Immunomedics, a biopharmaceutical company, for exclusive worldwide rights to develop, manufacture, and commercialize an antibody-drug conjugate (ADC) candidate for treating cancer, in a deal worth nearly \$2 billion. [Read More](#)

4. Pfizer to Close Australian Neulasta Biosimilar Plant by 2021

Pfizer will close its Adelaide, Australia manufacturing plant, gained through its 2015 \$17-billion acquisition of Hospira, by 2021. The plant produces pefilgrastim, the active ingredient in Pfizer's biosimilar candidate to Amgen's anti-cancer drug, Neulasta, one of Amgen's top-selling drugs with 2016 sales of \$3.9 billion. [Read More](#)

5. Astellas Makes Senior Appointments: Forms Division for CMO Management

Astellas Pharma has made some senior appointments, effective in April 2017, and has formed a division, Pharmaceutical Technology, to manage its contract manufacturing organization relationships. [Read More](#)

6. Novasep to Build \$29-Million Viral Vector Manufacturing Facility

Novasep, a contract manufacturing organization, has invested EUR 27 million (\$29 million) to build a commercial-scale manufacturing plant for viral vector-based therapeutics at its site in Seneffe, Belgium. The new plant is scheduled to be operational in early 2019. [Read More](#)

7. Hikma Expands Solid-Dose Manufacturing Plant

West-Ward Pharmaceuticals, a wholly owned subsidiary of Hikma Pharmaceuticals, is expanding its solid-dosage manufacturing facility in Columbus, Ohio, which Hikma gained in 2016 through its \$1.5-billion acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc., the generic businesses of Boehringer Ingelheim. [Read More](#)

8. [Aurobindo Acquires Four Biosimilars](#)

Aurobindo Pharma, an Indian generics and active pharmaceutical ingredients manufacturer, has acquired four cell culture-derived biosimilar candidates from TL Biopharmaceutical AG, based in Switzerland, including a biosimilar candidate to bevacizumab, the active ingredient in Roche's anti-cancer drug, Avastin (bevacizumab), which had 2016 sales of CHF 6.78 billion (\$6.76 billion). [Read More](#)

9. [FDA Accepts Mylan's Filing for Neulasta Biosimilar](#)

The FDA has accepted a biologics license application from Mylan and its partner, Biocon, for a proposed biosimilar to Amgen's anti-cancer drug, Neulasta (pegfilgrastim), one of Amgen's top-selling drugs with 2016 sales of \$3.9 billion. [Read More](#)

10. [Lannett Expands Controlled Substances Facilities](#)

Lannett, a generic drug manufacturer, will invest \$50 million to expand its wholly owned subsidiary, Cody Laboratories, a Cody, Wyoming-based manufacturer of active pharmaceutical ingredients and finished dosage forms of pain relief medications, which will include a new controlled substances manufacturing plant. [Read More](#)

[DCAT Week '17: Send the Right Signals in Your Business Meetings](#)

Effective communication is an imperative for successful business relationships, but are you sending the right signals in your important meetings with customers, suppliers, colleagues, and management? In a special [DCAT Business Builder](#) program at DCAT Week '17, learn how to master the skill of nonverbal communication with practical insight from body language expert Chris Ulrich, guest commentator on CNN and ABC's *Good Morning America*, who recently provided analysis of the nonverbal communication of the candidates during the US Presidential campaigns and debates. [Read More](#)

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org